Association between the skeletal muscle mass to visceral fat area ratio and metabolic dysfunction‐associated fatty liver disease: A cross‐sectional study of NHANES 2017–2018

Zhiliang Mai,Yinfei Chen,Hua Mao,Lisheng Wang
DOI: https://doi.org/10.1111/1753-0407.13569
IF: 4.53
2024-05-17
Journal of Diabetes
Abstract:Highlights Using data from the National Health and Nutrition Examination Survey, our study is among the first to investigate the relationship between sarcopenic obesity, represented by the skeletal muscle mass to visceral fat area ratio (SVR), and metabolic dysfunction‐associated steatotic liver disease (MASLD) in the US population. Measurements for SVR were obtained using dual‐energy x‐ray absorptiometry, and MASLD was diagnosed with controlled attenuation parameter scores and cardiometabolic risk factors. The present study revealed that lower levels of SVR were strongly associated with an increased risk of MASLD. Background and Aims Previous studies have shown that sarcopenic obesity (SO) was associated with nonalcoholic fatty liver disease (NAFLD). However, research is limited in the context of the NAFLD renamed as metabolic dysfunction‐associated steatotic liver disease (MASLD) defined by updated diagnostic criteria. The aim of this study was to use the index skeletal muscle mass to visceral fat area ratio (SVR) to describe SO in a large and representative US population (National Health and Nutrition Examination Survey 2017–2018) of adults and investigate their association with MASLD. Methods A total of 2087 individuals were included in the analysis. SVR was calculated according to the measurement of dual‐energy x‐ray absorptiometry and MASLD was diagnosed with controlled attenuation parameter scores and cardiometabolic risk factors. SVR was divided into tertiles. Logistic regression adjusted for confounders was used to evaluate the association between SVR and MASLD. Several sensitivity analyses were performed to test the robustness of our findings. Results In a multivariate logistic regression analysis, a significant association between SVR and MASLD was shown (odds ratio [OR]: 3.11, 95% confidence interval [CI]: 1.31–7.39, p = .010 for middle levels of SVR; OR: 3.82, 95% CI: 1.45–10.08, p = .007 for lowest levels of SVR). The sensitivity analyses confirmed that the association was robust. Conclusion Our findings imply that decreased SVR is linked to MASLD.
endocrinology & metabolism
What problem does this paper attempt to address?